Researchers from Landmark CGM Trials Receive “Excellence in Clinical Research Award” at JDRF’s 2011 Annual Conference

Researchers from Landmark CGM Trials Receive “Excellence in Clinical Research Award” at JDRF’s 2011 Annual Conference

May 19, 2011

Contact:           Joana Casas, JDRF Media Relations, 212.479.7560; mcasas@jdrf.org

 

Prestigious Award for Type 1 Diabetes Research

Presented by Mary Tyler Moore and S. Robert Levine, M.D.

 

Denver, Colo., May 19, 2011 – Mary Tyler Moore, international chairman of the Juvenile Diabetes Research Foundation (JDRF), and her husband, S. Robert Levine, M.D., presented the ninth annual Mary Tyler Moore and S. Robert Levine Excellence in Clinical Research Award to the JDRF Continuous Glucose Monitoring Study Group, a multi-center team of scientists, at JDRF’s Annual Conference today in Denver, Colorado.

The Excellence in Clinical Research Award recognizes outstanding clinical and translational research that has the potential to relieve the day-to-day burdens of type 1 diabetes, and ultimately achieve a life free of the disease and its complications. The prestigious award is named in honor of Ms. Moore – who has type 1 diabetes – and Dr. Levine for their extraordinary commitment to JDRF’s mission of finding better treatments and a cure for type 1 diabetes and its complications through the support of research.

The JDRF Continuous Glucose Monitoring Study Group is comprised of an extraordinary group of 75 dedicated individuals from 17 institutions. Together, they conducted a pivotal, multi-center clinical trial across the country, which demonstrated that people with type 1 diabetes who used a continuous glucose monitor (CGM) to help manage their disease experienced significant improvements in blood glucose control-a persistent challenge for people with the disease.

“The results of JDRF’s CGM trials ushered in a new era in diabetes management and in many ways changed the standards of diabetes care,” stated Ms. Moore and Dr. Levine. “The remarkable work that these groups of researchers were able to accomplish helped to solidify a foundation for the development of next-generation technologies that have the potential to improve quality of life and outcomes for people with type 1 diabetes even more. Each advance will help keep people with diabetes healthier as we sustain our dedication to finding a cure.”

CGMs are one of the most promising recent technological advances in diabetes care, and are an important component in the development of an artificial pancreas. Unlike finger sticks, which provide only periodic snapshots of glucose control, a CGM provides glucose readings continuously throughout the day and night. Importantly, a CGM can show glucose trends and can sound alarms when blood glucose levels are too high or too low. To prove the promise of CGMs, JDRF funded this multi-disciplinary, multi-center group of researchers and clinicians to independently test the impact of CGM use in children and adults with type 1 diabetes.

A total of 16 high-impact publications demonstrating the positive impact that CGM devices have in diabetes management have been authored and published by the study group.

Listed in order of number of patients enrolled with clinical center name, city, and state, this year’s award recipients are as follows. Personnel are listed as (PI) for Principal Investigator, (I) for co-Investigator and (C) for Coordinators:

 

Diabetes Care Center, University of Washington, Seattle, Washington:
Irl B. Hirsch, M.D. (PI); Lisa K. Gilliam, M.D., Ph.D. (I); Kathy Fitzpatrick, R.N., M.N., C.D.E. (C); Dori Khakpour, R.D., C.D., C.D.E. (C)

Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut:
Stuart A. Weinzimer, M.D. (PI); William V. Tamborlane, M.D. (I); Brett Ives, M.S.N., A.P.R.N. (C); Joan Bosson-Heenan (C)

Adult Section, Joslin Diabetes Center; Boston, Massachusetts:
Howard Wolpert, M.D. (PI); Greeshma Shetty, M.D. (I); Astrid Atakov-Castillo (C); Judith Giusti, M.S., R.D., L.D.N., C.D.E. (C); Stacey O’Donnell, R.N., C.D.E. (C); Suzanne Ghiloni, R.N., C.D.E. (C)

Atlanta Diabetes Associates, Atlanta, Georgia:
Bruce W. Bode, M.D. (PI); Kelli O’Neil, C.D.E. (C); Lisa Tolbert, R.N., M.N., C.D.E. (C)

Nemours Children’s Clinic, Jacksonville, Florida:
Tim Wysocki, Ph.D. (co-PI); Larry A. Fox, M.D. (co-PI); Nelly Mauras, M.D. (I); Kimberly Englert, R.N. (C); Joe Permuy, M.S.N., A.R.N.P. (C)

Division of Pediatric Endocrinology and Diabetes, Stanford University, Stanford, California:
Bruce Buckingham, M.D. (PI); Darrell M. Wilson, M.D. (I); Jennifer Block, R.N., C.D.E. (C); Kari Benassi, R.N., N.P. (C)

Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, Iowa:
Eva Tsalikian, M.D. (PI); Michael Tansey, M.D. (I); Debra Kucera, A.R.N.P., C.P.N.P. (C); Julie Coffey, A.R.N.P., C.P.N.P. (C); Joanne Cabbage (C)

Pediatric, Adolescent and Young Adult Section, Joslin Diabetes Center, Boston, Massachusetts:
Lori Laffel, M.D., M.P.H., (PI); Kerry Milaszewski, R.N., C.D.E. (C); Katherine Pratt (C); Elise Bismuth, M.D., M.S., (C); Joyce Keady, M.S.N., C.P.N.P. (C); Margie Lawlor, M.S., C.D.E. (C)

Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver, Colorado:
H. Peter Chase,M.D. (PI); Rosanna Fiallo-Scharer, M.D. (I); Paul Wadwa, M.D. (I); Laurel Messer, R.N., C.D.E. (C); Victoria Gage, R.N. (C); Patricia Burdick (C)

Departments of Pediatric Endocrinology and Research and Evaluation, Kaiser Permanente, San Diego and Pasadena, California:
Jean M. Lawrence, Sc.D., M.P.H., M.S.S.A. (co-PI); Robert Clemons, M.D. (co-PI); Michelle Maeva, R.N., C.D.E. (C); Bonnie Sattler, M.S., R.D. (C)

Coordinating Center: Jaeb Center for Health Research, Tampa, Florida:
Roy W. Beck, M.D., Ph.D.; Katrina J. Ruedy, M.S.P.H.; Craig Kollman, Ph.D.; Dongyuan Xing, M.P.H.; Judy Sibayan, M.P.H.

University of Minnesota Central Laboratory, Minneapolis, Minnesota:
Michael Steffes, M.D., Ph.D.; Jean M. Bucksa, C.L.S.; Maren L. Nowicki, C.L.S.; Carol Van Hale, C.L.S.;  Vicky Makky, C.L.S.

Cost-effectiveness investigators: National Opinion Research Center University of Chicago, Chicago, Ilinois:
Michael O’Grady, Ph.D.; Elbert Huang, M.D., M.P.H.; Anirban Basu, Ph.D.; David O. Meltzer, M.D., Ph.D.; Lan Zhao. Ph.D.

University of Michigan, Ann Arbor, Michigan:
Joyce Lee, M.D., M.P.H.

Juvenile Diabetes Research Foundation, Inc., New York, New York:
Aaron J. Kowalski, Ph.D.

Operations Committee: Lori Laffel, M.D., M.P.H. (co-chair); William V. Tamborlane, M.D. (co-chair); Roy W. Beck, M.D., Ph.D.; Aaron J. Kowalski, Ph.D.; Katrina J. Ruedy, M.S.P.H.

Data and Safety Monitoring Board: Ruth S. Weinstock, M.D., Ph.D. (chair); Barbara J. Anderson, Ph.D.; Davida Kruger, M.S.N., A.P.R.N.; Lisa LaVange, Ph.D.; Henry Rodriguez, M.D.

 

About JDRF

JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is now the largest charitable supporter of T1D research. The goal of JDRF research is to improve the lives of all people affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal.

Since its founding in 1970, JDRF has awarded more than $1.7 billion to diabetes research. Past JDRF efforts have helped to significantly advance the care of people with this disease, and have expanded the critical scientific understanding of T1D. JDRF will not rest until T1D is fully conquered. More than 80 percent of JDRF’s expenditures directly support research and research-related education.